DexCom (DXCM), MD Revolution Unite to Boost Diabetes Management
DexCom (DXCM) and MD Revolution collaborate to integrate Dexcom's continuous glucose monitoring systems with MD Revolution's remote care management platform to boost remote diabetes management.
SLB, DXCM, CRH: The Economy is Relatively Healthy
Economic trends and earnings continue to drive most of the conversations, notes Tyler Ellegard. He discusses the impact upcoming earnings could have on the markets.
DexCom Is Pricey For A Reason - Its Growth Story Reflects That
DexCom received FDA approval for its continuous glucose monitoring product, Stelo, to be available over the counter, making it the first OTC CGM product ever. The company has demonstrated robust gr...
DexCom, Inc. (DXCM) is Attracting Investor Attention: Here is What You Should Know
DexCom (DXCM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
DexCom (DXCM) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, DexCom (DXCM) stood at $136.65, denoting a -0.94% change from the preceding trading day.
DexCom Stock Gains from GLP-1 Diabetic Users
DexCom Inc. NASDAQ: DXCM is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People with diabetes use CGM systems to monitor t...
DexCom (DXCM) Upgraded to Buy: What Does It Mean for the Stock?
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
DexCom (DXCM) Hits 52-Week High: What's Driving the Stock?
Investors are optimistic about DexCom's (DXCM) strong product portfolio.
Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?
Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.
DexCom, Inc. (DXCM) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching DexCom (DXCM) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
DexCom (DXCM) Stock Sinks As Market Gains: Here's Why
DexCom (DXCM) closed at $134.17 in the latest trading session, marking a -0.41% move from the prior day.
Is It Worth Investing in DexCom (DXCM) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts oft...
DexCom (DXCM) Sees a More Significant Dip Than Broader Market: Some Facts to Know
The latest trading day saw DexCom (DXCM) settling at $133.04, representing a -1.63% change from its previous close.
2 Medical Device Stocks to Buy Hand Over Fist in March
Medtronic is a leading medical device maker that continues to get bigger and more diversified. DexCom's continuous glucose monitoring devices are crucial for diabetics, enabling strong growth.
DexCom (DXCM) Soars 10% This Week: What's Fueling the Gain?
A recent approval for DexCom's (DXCM) new CGM device boosts the prospects of the company by broadening the targeted market. Shares gain as investors see strong potential for growth going forward.
Related Companies